In some countries such as France, Italy, Spain and the Balkan region, Menarini Group will lead the commercialisation effort, as part of an exclusive licensing agreement signed with Glenmark
The centralized marketing authorization granted by the EC is valid in all EU Member
Projects 5X revenue growth by 2028, accelerates global market leadership and paves the way for IPO
Phase 1 dosing is expected to finish by the end of 2025
The company’s virgin PET chips plant in Egypt, commissioned in Q4 FY25, achieved 74.8 per cent capacity utilization in its first full quarter. In India, the Panipat facility operated at 96.6 per cent utilization
EBITDA stood at Rs. 100.1 crore with a margin of 16.1 per cent
The company reported revenue from operations at Rs. 6,573.7 crore, up 6 per cent YoY
The agreement complements other PPAs for Sandoz production sites globally
Ranibizumab is a recombinant humanized IgG1 monoclonal antibody fragment that binds to and inhibits vascular endothelial growth factor A
Aurobindo Pharma’s US formulations revenue slipped 1.9% on a year-on-year basis to Rs. 3,488 crore
Subscribe To Our Newsletter & Stay Updated
